🇺🇸 FDA
Company

Sunshine

Sunshine Biopharma

SBFM biotech USA

Quick answer

Sunshine is a biotech company (SBFM) headquartered in FORT LAUDERDALE, FL, USA with 24 tracked pipeline programs.

Pipeline (24)

project

1% Clascoterone Cream

Acne Vulgaris

Phase 3 · small_molecule · active

1 trials project

5% minoxidil foam

Androgenetic Alopecia

Phase 3 · small_molecule · active

1 trials project

601 1.25mg

Branch Retinal Vein Occlusion

Phase 3 · small_molecule · completed

2 trials project

608

Axial Spondyloarthritis, Non-Radiographic

Phase 3 · small_molecule · active

1 trials project

608 Q2W

Plaque Psoriasis Patients

Phase 3 · small_molecule · active

1 trials project

608 Q2W

Psoriasis

Phase 3 · small_molecule · completed

1 trials project

608 dose

Ankylosing Spondylitis

Phase 3 · small_molecule · active

1 trials project

610

Asthma

Phase 3 · small_molecule · active

2 trials project

611

Pulmonary Disease, Chronic Obstructive (COPD)

Phase 3 · small_molecule · active

1 trials project

611

Dermatitis, Atopic

Phase 3 · small_molecule · active

3 trials project

611

Sinusitis

Phase 3 · small_molecule · active

2 trials project

Clascoterone

Acne Vulgaris

Phase 3 · small_molecule · active

1 trials project

Clifutinib

Leukemia, Acute Myeloid (AML)

Phase 3 · small_molecule · active

1 trials project

EPREX®

Renal Anemia

Phase 3 · small_molecule · completed

1 trials project

Etanercept

Rheumatoid Arthritis

Phase 3 · small_molecule · active

1 trials project

HEC585

Idiopathic Pulmonary Fibrosis (IPF)

Phase 3 · small_molecule · active

1 trials project

HEC74647PA+HEC110114

Chronic HCV Infection

Phase 3 · small_molecule · completed

1 trials project

Human Erythropoiesis Injection (CHO cell)

Kidney Failure, Chronic

Phase 3 · small_molecule · active

1 trials project

Insulin Degludec and Insulin Aspart

Diabetes

Phase 3 · small_molecule · completed

1 trials project

Lerotinib

Esophageal Cancer

Phase 3 · small_molecule · active

1 trials project

Mitizodone Phosphate tablets

Depressive Disorder, Major

Phase 3 · small_molecule · active

1 trials project

Nalfurafine Hydrochloride

Uremic Pruritus

Phase 3 · small_molecule · active

1 trials project

Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg

Acute Gout

Phase 3 · small_molecule · active

2 trials project

SOF

Chronic HCV Infection

Phase 3 · small_molecule · completed

2 trials

Drugs (12)

drug

apixaban

APIXABAN

 drug

brivaracetam

BRIVARACETAM

 drug

clarithromycin

CLARITHROMYCIN

 drug

duloxetine hydrochloride

DULOXETINE HYDROCHLORIDE

 drug

entacapone

ENTACAPONE

 drug

febuxostat

FEBUXOSTAT

 drug

insulin glargine-aldy

LANGLARA

 drug

linagliptin

JENTADUETO

 drug

metoprolol succinate

METOPROLOL SUCCINATE

 drug

mirabegron

MIRABEGRON

 drug

moxifloxacin hydrochloride

MOXIFLOXACIN HYDROCHLORIDE

 drug

rivaroxaban

RIVAROXABAN

Patents (8)

patent

US 12428432

Thienopyrimidine derivatives having stereo configurations and use thereof in med

Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12428389

Diarylamide compound and application thereof

Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12384853

Anti-HER2/PD1 bispecific antibody

Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12324812

Glucopyranosyl derivatives and their uses

Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12319748

Antibody binding to human HER2 and preparation method and use thereof

Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12312348

RET inhibitors, pharmaceutical compositions and uses thereof

Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12269886

Tetravalent bispecific antibody against PD-1 and PD-L1

Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12258317

Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof

Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)